Similarly, in cardiovascular diseases, targeting PCSK9 lowers cholesterol levels, while NLRP3 knockout reduces myocardial inflammation, improving atherosclerosis and decreasing cardiovascular event risk (Makhmudova et al., 2024). Here, PCSK9 is linked to atherosclerosis.